ELSEVIER
SAUNDERS

NURSING
CLINICS
OF NORTH AMERICA

Nurs Clin N Am 41 (2006) 737–744

Index

Note: Page numbers of article titles are in **boldface** type.

A

Adolescents, diabetes in girls during puberty, 549–550
  with type 1 diabetes, family interventions for, 626–631
    self-management and family involvement in, 522–523
  with type 2 diabetes, family interventions for, 631–635

Alpha-Glucosidase inhibitors, oral, for type 2 diabetes, 593–594

American Association of Diabetes Educators, Outcomes Task Force of, evaluating outcome of diabetes self-management education, 664–666

Anxiety disorders, in adults with diabetes, 674

Autonomic neuropathies, diabetic, 707–715

B

Basal insulin, 599–600

Behavioral family systems therapy, for adolescents with type 1 diabetes, 630–631

Behavioral interventions, for diabetes self-management, **641–654**
  current trends in self-management, 647–649
  patient-centered patient education model, 646–647
  to support diabetes self-management, 643–646

Beta-cell secretion, defects in, in pathophysiology of type 2 diabetes, 539–540

Biguanides, oral, for type 2 diabetes, 591–592

Blood glucose monitoring, in type 1 diabetes, 520
  national standards for, 660–661

Bolus insulins, 600

C

Cardiovascular disease, diabetes mellitus and, **681–695**
  detection of coronary heart disease, 684–686
  management of chronic coronary heart disease, 689–693
  medical and surgical interventions for acute manifestations of coronary heart disease, 686–689
  prevention of coronary heart disease, 682–684
  in women with diabetes, 559–560

Cardiovascular risk, in diabetes patients, 491–492
  dyslipidemia, 492–494
  hypertension, 491–492

Cognitive deficits, in adults with diabetes, 676

Combination therapy, with oral medications for type 2 diabetes, 595–596

Complications, of diabetes, acute and chronic, in type 1 diabetes, 523–525
  acute, national standards for management of, 661–662
  costs of, 500–502
  diabetic nephropathy, 726–730
  diabetic neuropathy, **697-717**
  diabetic retinopathy, 722–726
  epidemiologic perspective on risk of developing, **487–498**
  microvascular, **719–736**
    cutaneous and oral manifestations, 730–732
    future therapies and implications, 732–734
    nephropathy, 726–730
    pathophysiologies, 721–722
    preventive strategies, 721
    retinopathy, 722–726
    risk factors for, 720
  pathophysiology of, in type 1 diabetes, 541–542

0029-6465/06/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/S0029-6465(06)00088-0

Congenital malformations, diabetes-related, 551–552

Coping abilities, in adults with diabetes, 669

Coronary heart disease, diabetes mellitus and, **681–695**
  detection of, 684–686
  management of chronic, 689–693
  medical and surgical interventions for acute manifestations of, 686–689
  prevention of, 682–684

Cost-effectiveness analysis, of interventions designed to prevent diabetes or its complications, 507–508

Costs, of diabetes. *See* Economics.

Cutaneous manifestations, of microvascular complications of diabetes, 730–732

D

Depression, in adults with diabetes, 671–674

Dermopathy, diabetic, 731–732

Diabetes, 487–736
  behavioral interventions, **641–654**
    current trends in self-management, 647–649
    patient-centered patient education model, 646–647
    to support diabetes self-management, 643–646
  cardiovascular disease and, **681–695**
    detection of coronary heart disease, 684–686
    management of chronic coronary heart disease, 689–693
    medical and surgical interventions for acute manifestations of coronary heart disease, 686–689
    prevention of coronary heart disease, 682–684
  classification of, 532–534
  economics of, **499–511**
    direct costs of, 500–501
    impact of cost on patients' service use and health outcomes, 502–504
    indirect costs of, 501–502
    predicting diabetes-related costs, 502
    structuring insurance benefits to promote more effective care, 504–507
    use of cost-effectiveness analysis to evaluate interventions for, 507–508
  epidemiologic perspective on risks for, **487–498**
    cardiovascular risk, 491–492
      dyslipidemia, 492–494
      hypertension, 491–492
    Diabetes Surveillance System, 492–494
    etiology, 488–490
    prevalence, 488
  family interventions for, **625–639**
    factors to consider in family care, 635–636
    with adolescents with type 2 diabetes, 631–635
    with children and adolescents with type 1 diabetes, 626–631
      behavioral family systems therapy, 630–631
      family-focused teamwork, 629–630
      family-to-family network, 628
      parent-minor intervention, 629
  microvascular complications of, **719–736**
    cutaneous and oral manifestations, 730–732
    future therapies and implications, 732–734
    nephropathy, 726–730
    pathophysiologies, 721–722
    preventive strategies, 721
    retinopathy, 722–726
    risk factors for, 720
  neuropathies, **697–717**
    autonomic, 707–715
    classification, 698–699
    focal and multifocal, 705–707
    importance of foot care education, 705
    pathophysiology, 697–698
    sensory, 699–705
    understanding clinical presentation of, 699
  psychosocial and psychiatric challenges of, **667–680**
  self-management education, **655–666**
    definition of, 655–656
    national standards for, 656–664
    Outcomes Task Force, 664–666
  type 1, **513–530**
    diagnosis, 515–516
    epidemiology, 513
    genetics, 514
    medical and nursing management, 516–517
      blood glucose monitoring, 520

insulin therapy, 517–519
nutrition for, 520
physical activity and exercise, 520–521
pathophysiology, 514–515
pharmacologic interventions for, **589–604**
self-management and family involvement, 521–523
acute and chronic complications, 523–525
adolescents, 522–523
infants and toddlers, 521
major developmental issues in children and adolescents, 526–527
preschool and early school-aged children, 521–522
school-aged children, 522
type 2, **531–547**
acute complications, 543
diagnostic criteria for, 536–537
lifestyle interventions, **567–588**
for diabetes prevention, 568–578
for diabetes treatment, 578–583
translation of research on, 583–585
metabolic syndrome and insulin resistance, 535–536
pathophysiology, 539–542
pharmacologic interventions for, **589–604**
prediabetes, management of, 545
risk factors and screening, 537–539
signs and symptoms, 542–543
treatment, 544–545
in youth, 545
vulnerable populations with, **605–623**
vulnerable populations with, trends in, diabetes status, 607–608
intervention planning, 615–616
mental health, 610
patient-provider interactions, 613–615
perceptions and beliefs, 608–609
recommendations for, 616–618
research tools and educational materials, 615
self-management behaviors, 610–611
self-management education, 612–613
social support, 611–612
symptoms, 609–610
women and, **549–565**
in older women, 558–561
in puberty, 549–550
in the reproductive years, 550–558

Diabetes Surveillance System, 492–494

Diet, lifestyle interventions for prevention of type 2 diabetes, 568–578
lifestyle interventions for treatment of type 2 diabetes, 578–583

Distal symmetric peripheral neuropathy, 699–705

Dyslipidemia, in diabetes patients, 492

E

Eating, disordered, in adults with diabetes, 674–675

Economics, of diabetes, **499–511**
direct costs of, 500–501
impact of cost on patients' service use and health outcomes, 502–504
indirect costs of, 501–502
predicting diabetes-related costs, 502
structuring insurance benefits to promote more effective care, 504–507
use of cost-effectiveness analysis to evaluate interventions for, 507–508

Education, patient, for diabetes self-management, **655–666**
definition of, 655–656
national standards for, 656–664
Outcomes Task Force, 664–666

Epidemiology, of diabetes, perspectives on risk for, **487–498**
cardiovascular risk, 491–492
dyslipidemia, 492–494
hypertension, 491–492
Diabetes Surveillance System, 492–494
etiology, 488–490
prevalence, 488
of type 1 diabetes, 513

Ethnic groups, vulnerable populations with diabetes mellitus, **605–623**

Etiology, of diabetes, 488–490

Exercise, for type 1 diabetes, 520–521

F

Family involvement, and self-management in type 1 diabetes, 521–523
  acute and chronic complications, 523–525
  adolescents, 522–523
  infants and toddlers, 521
  major developmental issues in children and adolescents, 526–527
  preschool and early school-aged children, 521–522
  school-aged children, 522
interventions for families with diabetes, factors to consider in family care, 635–636
  with adolescents with type 2 diabetes, 631–635
  with children and adolescents with type 1 diabetes, 626–631
    behavioral family systems therapy, 630–631
    family-focused teamwork, 629–630
    family-to-family network, 628
    parent-minor intervention, 629

Foot ulcers, as complication of diabetes, 731–732
  importance of foot care education, 705

G

Genetics, of type 1 diabetes, 514

Gestational diabetes. *See also* Pregnancy.
  classification of, 534, 550–551
  lactation in women with, 555
  management of, 552–554
  national standards for management of, 663–664
  postpartum care, 555–556

Glucose. *See* Blood glucose monitoring.

Glucosidase inhibitors, alpha-, oral, for type 2 diabetes, 593–594

Glycemic control, hemoglobin A1c changes as measure of lifestyle interventions for type 2 diabetes, 578–583

Goal setting, for diabetics, national standards for problem solving and, 662–663

H

Hemoglobin A1c changes, as measure of lifestyle interventions for treatment of type 2 diabetes, 578–583

Hormone replacement therapy, in women with diabetes, 559

Hypertension, in diabetes patients, 491–492

Hypoglycemia, fear of, in adults with diabetes, 671

I

Incretin-based therapies, for type 2 diabetes, 596–597

Infants, with type 1 diabetes, self-management and family involvement in, 521

Inhaled insulin, 601–602

Insulin resistance, and metabolic syndrome, 535–536
  pathogenesis of, 540–541
  psychologic, 670

Insulin therapy, for type 1 and type 2 diabetes, 598–602
  basal, 599–600
  bolus, 600
  inhaled, 601–602
  premixed, 600–601
for type 1 diabetes, 517–519

Insurance coverage, structuring benefits to provide more effective diabetes care, 504–507

K

Kidney disease, diabetic nephropathy, 726–730

L

Lifestyle interventions, for type 2 diabetes, **567–588**
  for prevention, 568–578
  for treatment, 578–583
  translation of research on, 583–585

Low income, vulnerable populations with diabetes mellitus, **605–623**

M

Maturity-onset diabetes, classification of, 534

Medicare, structuring benefits to provide more effective diabetes care, 504–507

Medications. *See* Pharmacologic interventions.

Meglitinide analogues, oral, for type 2 diabetes, 594–595

Menopause, diabetes and, 558–559

Menstrual cycle, effects on glucose control in women with diabetes, 556–557

Mental health, in vulnerable populations with diabetes, 610

Metabolic syndrome, 535–536
diagnostic criteria for, 537

Metabolism, during pregnancy, impact of diabetes on, 551

Microvascular complications, of diabetes, **719–736**
cutaneous and oral manifestations, 730–732
future therapies and implications, 732–734
nephropathy, 726–730
pathophysiologies, 721–722
preventive strategies, 721
retinopathy, 722–726
risk factors for, 720

N

Nephropathy, diabetic, 726–730

Neuropathies, diabetic, **697–717**
See also Microvascular complications.
autonomic, 707–715
classification, 698–699
focal and multifocal, 705–707
importance of foot care education, 705
pathophysiology, 697–698
sensory, 699–705
understanding clinical presentation of, 699

Nutritional management, for type 1 diabetes, 520
of diabetes, national standards for, 651–659

O

Obesity, in pathogenesis of type 2 diabetes, 541

Ocular complications, of diabetes, diabetic retinopathy, 722–726

Older women, diabetes in, 558–561
cardiovascular disease and, 559–560
hormone replacement therapy, 559
menopause, 558–559
osteoporosis and, 561

Oral manifestations, of microvascular complications of diabetes, 730–732

Oral medications, for type 1 and type 2 diabetes, **589–604**
alpha-glucosidase inhibitors, 593–594
biguanides, 591–592
combination therapy, 595–596
incretin-based therapies, 596–597
meglitinide analogues, 594–595
pramlintide, 597–598
sulfonylureas, 590–591
thiazolidinediones, 592–593

Osteoporosis, in women with diabetes, 561

Outcomes, in diabetes, impact of cost on, 502–504

Outcomes Task Force, of AADE, and outcome of diabetes self-management education, 664–666

P

Pathophysiology, of microvascular complications of diabetes, 721–722
of type 1 diabetes, 514–515
of type 2 diabetes, 539–542
defects in beta-cell secretion, 539–540
obesity, 541
of chronic complications, 541–542
pathogenesis of insulin resistance, 540–541

Patient education, for diabetes self-management, **655–666**
definition of, 655–656
national standards for, 656–664
Outcomes Task Force, 664–666

Patient-provider interactions, in vulnerable populations with diabetes, 613–615

Periodontal disease, as a complication of diabetes, 730–732

Pharmacologic interventions, for type 1 and type 2 diabetes, **589–604**
alpha-glucosidase inhibitors, 593–594
biguanides, 591–592
combination therapy, 595–596

Pharmacologic (*continued*)
incretin-based therapies, 596–597
insulin, 598–602
basal, 599–600
bolus, 600
inhaled, 601–602
premixed, 600–601
meglitinide analogues, 594–595
pramlintide, 597–598
sulfonylureas, 590–591
thiazolidinediones, 592–593

Physical activity, for diabetes management, national standards for, 659–660
for type 1 diabetes, 520–521
lifestyle interventions for prevention of type 2 diabetes, 568–578
lifestyle interventions for treatment of type 2 diabetes, 578–583

Polycystic ovarian syndrome, diabetes and, 557–558

Pramlintide, for type 2 diabetes, 597–598

Preconception care, in diabetics, national standards for, 663–664

Prediabetes, classification of, 534
management of, 545

Pregnancy, diabetes during, 550–556
classification of, 550–551
congenital malformations related to, 551–552
fuel metabolism, 551
gestational diabetes mellitus, 552
management of, 552–556
complications, 554–555
lactation, 555
postpartum, 555–556
national standards for management of, 663–664, 550–556

Premixed insulins, 600–601

Preschool-aged children, with type 1 diabetes, self-management and family involvement in, 521–522

Prevalence, of diabetes, 488

Prevention, of microvascular complications of diabetes, 721

Psychiatric comorbidities, in adults living with diabetes, 671–676
anxiety disorders, 674
cognitive deficits, 676
depression, 671–674
disordered eating, 674–675
schizophrenia, 675

Psychologic insulin resistance, 670

Psychosocial issues, in diabetes, for adults living with diabetes, **667–680**
coping ability, 669
diabetes-specific stress and distress, 669–670
diagnosis of, 668
fear of high blood glucose and complications, 671
fear of hypoglycemia, 671
psychiatric comorbidities, 671–676
anxiety disorders, 674
cognitive deficits, 676
depression, 671–674
disordered eating, 674–675
schizophrenia, 675
psychologic insulin resistance, 670
stress and, 668–669
national standards for management of, 663

Puberty, diabetes in girls during, 549–550

Q

Quality-adjusted life years, in cost-effectiveness analysis of interventions designed to prevent diabetes, 507–508

R

Racial disparities, vulnerable populations with diabetes mellitus, **605–623**

Rapid-acting insulins, 600

Reproductive years, for women, diabetes in, 550–558
effects of menstrual cycle on glucose control, 556–557
polycystic ovarian syndrome, 557–558
pregnancy, 550–556

Research, on lifestyle interventions for type 2 diabetes, translation of, 583–585

Retinopathy, diabetic, 722–726

Risk factors, and screening recommendations, 537–539
for developing diabetes and complications, **487–498**
for microvascular complications of diabetes, 720

Risk reduction, for diabetes, national standards for management of, 662

Rural areas, vulnerable populations with diabetes mellitus, **605–623**

S

Schizophrenia, in adults with diabetes, 675

School-aged children, with type 1 diabetes, self-management and family involvement in, 522

Screening recommendations, for diabetes, 537-539

Self-management, of diabetes, and family involvement in type 1 diabetes, 521–523
  acute and chronic complications, 523–525
  adolescents, 522–523
  infants and toddlers, 521
  major developmental issues in children and adolescents, 526–527
  preschool and early school-aged children, 521–522
  school-aged children, 522
behavioral interventions for, **641–654**
  current trends in self-management, 647–649
  patient-centered patient education model, 646–647
  to support diabetes self-management, 643–646
in vulnerable populations with diabetes, 610–611
patient education for, **655–666**
  definition of, 655–656
  national standards for, 656–664
  Outcomes Task Force, 664–666

Sensory neuropathies, diabetic, 699–705

Social support, in vulnerable populations with diabetes, 611–612

Stress, in adults with diabetes, 668–669
  diabetes-specific stress and distress, 669–670

Sulfonylureas, oral, for type 2 diabetes, 590–591

Symptoms, of type 2 diabetes, 542–543
  in vulnerable populations, 609–610

T

Thiazolidinediones, oral, for type 2 diabetes, 592–593

Toddlers, with type 1 diabetes, self-management and family involvement in, 521

Treatment, of type 1 diabetes, medical and nursing management, 516–517
  blood glucose monitoring, 520
  insulin therapy, 517–519
  nutrition for, 520
  physical activity and exercise, 520–521
of type 2 diabetes, 544–545
  in youths, 545
pharmacologic interventions for type 1 and type 2 diabetes, **589–604**
  alpha-glucosidase inhibitors, 593–594
  biguanides, 591–592
  combination therapy, 595–596
  incretin-based therapies, 596–597
  insulin, 598–602
    basal, 599–600
    bolus, 600
    inhaled, 601–602
    premixed, 600–601
  meglitinide analogues, 594–595
  pramlintide, 597–598
  sulfonylureas, 590–591
  thiazolidinediones, 592–593

Type 1 diabetes, **513–530**
  classification of, 532
  diagnosis, 515–516
  epidemiology, 513
  genetics, 514
  in children and adolescents, family interventions for, 626–631
    behavioral family systems therapy, 630–631
    family-focused teamwork, 629–630
    family-to-family network, 628
    parent-minor intervention, 629
  medical and nursing management, 516–517
    blood glucose monitoring, 520
    insulin therapy, 517–519
    nutrition for, 520
    physical activity and exercise, 520–521
  pathophysiology, 514–515
  pharmacologic interventions for, **589–604**
  self-management and family involvement, 521–523
    acute and chronic complications, 523–525
    adolescents, 522–523
    infants and toddlers, 521
    major developmental issues in children and adolescents, 526–527
    preschool and early school-aged children, 521–522
    school-aged children, 522

Type 2 diabetes. *See* Diabetes.

U

Underserved areas, vulnerable populations with diabetes mellitus, **605–623**

V

Vision, diabetic retinopathy and, 722–726

Vulnerable populations, with diabetes mellitus, **605–623**

W

Weight loss, lifestyle interventions for prevention of type 2 diabetes, 568–578
lifestyle interventions for treatment of type 2 diabetes, 578–583

Women, diabetes in, **549–565**
in older women, 558–561
cardiovascular disease and, 559–560
hormone replacement therapy, 559
menopause, 558–559
osteoporosis and, 561
in puberty, 549–550
in the reproductive years, 550–558
effects of menstrual cycle on glucose control, 556–557
polycystic ovarian syndrome, 557–558
pregnancy and, 550–556

Y

Youth, type 1. *See* Type 1 diabetes.
type 2 diabetes in, 533–534
management of, 545